WEST SACRAMENTO, CA - Lipomics Technologies, Inc., a privately held company that specializes in clinical diagnostic development, announced today that it is engaged in a research collaboration with Joslin Diabetes Center.
The collaboration will initially focus on two research programs. The first is a study on insulin resistant patients with a family history of type 2 diabetes. The primary objective is to identify predictive markers of disease that can be translated into blood based diagnostics.
The second study will focus on understanding the effects of gastric bypass surgery on insulin sensitivity. Both research programs originate from the laboratories of Mary Elizabeth Patti, MD, and Allison Goldfine, both Assistant Professors of Medicine, at Harvard Medical School and Investigators at Joslin Diabetes Center.
"We are excited about this collaboration and anticipate that the unique technology at Lipomics will generate interesting results and advance our research programs, as we believe that lipid metabolism is a critical component of diabetes risk," said Dr. Patti.
Lipomics is developing diagnostic monitoring tools for the management of type 2 diabetes. "It is an honor to work with Dr. Patti and a premier research institution like the Joslin Diabetes Center. We believe that this collaboration will provide access to valuable clinical samples in support of our diagnostic development programs," said Steve Watkins, Ph.D., chief executive officer at Lipomics.
Lipomics will retain certain rights to develop diagnostic applications based on data emerging from these studies.
About Joslin Diabetes Center
Joslin Diabetes Center is the world's largest diabetes clinic, diabetes research center and provider of diabetes education. Founded in 1898, Joslin is an independent nonprofit institution affiliated with Harvard Medical School. Joslin research is a team of more than 300 people at the forefront of discovery aimed at preventing and curing diabetes. Joslin Clinic, affiliated with Beth Israel Deaconess Medical Center in Boston, the nationwide network of Joslin Affiliated Programs, and the hundreds of Joslin educational programs offered each year for clinicians, researchers and patients, enable Joslin to develop, implement and share innovations that immeasurably improve the lives of people with diabetes. As a nonprofit, Joslin benefits from the generosity of donors in advancing its mission. For more information on Joslin, call 1-800-JOSLIN-1 or visit www.joslin.org.
About Lipomics
Lipomics Technologies provides industry-leading metabolic assessments for drug research, clinical diagnostics and personalized medicine. The Company's proprietary analytical technologies generate comprehensive, accurate and quantitative profiles of lipid metabolites.
A broad range of bioinformatics and analytical tools map these profiles to the underlying biochemical pathways. Through these tools, Lipomics delivers deep and rich knowledge about biological and metabolic changes induced by disease, drug action, nutritional or lifestyle influences.
In partnership with pharmaceutical, biotechnology and nutrition companies, Lipomics uses its technologies to discover new diagnostic biomarkers, improve drug discovery, develop companion diagnostics and enable individualized health management.
